SCHEMBL3760993

SCHEMBL3760993

CSc1ccc(C(=O)NC2CCN(CC(=O)N3CCN(C4CCC4)CC3)CC2)cc1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.58
DRD2 P14416 1/20 0.50
DRD4 P21917 1/20 0.50
HRH3 Q9Y5N1 6/20 0.46
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
MEN1 O00255 2/20 0.43
SIGMAR1 Q99720 2/20 0.42
F10 P00742 1/20 0.42
SLC6A4 P31645 2/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A3 Q01959 1/20 0.42
CARM1 Q86X55 1/20 0.42
PRMT6 Q96LA8 1/20 0.42
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ALDH1A1 P00352 2/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3767807 0.94 DRD2 (0.56) KMT2ADRD2DRD4HRH3MEN1
SCHEMBL3770279 0.90 KMT2A (0.56) KMT2ADRD2DRD4HRH3NPC1
SCHEMBL3773424 0.89 KMT2A (0.61) KMT2ADRD4HRH3NPC1RAB9A
SCHEMBL3762894 0.86 KMT2A (0.57) KMT2ADRD4MEN1SIGMAR1CARM1
SCHEMBL13006775 0.86 KMT2A (0.79) KMT2ADRD4HRH3MEN1F10
SCHEMBL3779305 0.86 KMT2A (0.58) KMT2ADRD2HRH3NPC1RAB9A
SCHEMBL3774069 0.85 KMT2A (0.57) KMT2AHRH3NPC1RAB9AMEN1
SCHEMBL3768221 0.84 KMT2A (0.56) KMT2ADRD2DRD4HRH3NPC1
SCHEMBL3768050 0.84 KMT2A (0.49) KMT2ADRD2DRD4HRH3
SCHEMBL3780450 0.84 KMT2A (0.64) KMT2AHRH3MEN1ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 KMT2A 242/4885DRD2 473/4885DRD4 1242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.